Table 3.

Summary of AEs.

n (%)a	Olaparib (n = 224)
Any AE	222 (99.1)
Grade ≥3	109 (48.7)
Treatment-related AE	220 (98.2)
Grade ≥3	96 (42.9)
Any serious AE	57 (25.4)
Treatment-related serious AE	39 (17.4)
Any AE leading to treatment discontinuation	22 (9.8)
Treatment-related AE leading to treatment discontinuation	21 (9.4)
Any AE occurring in >10% of patients	Grade 1 or 2	Grade 3 or 4
Anemia	115 (51.4)	56 (25.0)
Nausea	120 (53.6)	1 (0.4)
Leukopenia	46 (20.5)	8 (3.6)
Vomiting	52 (23.2)	5 (2.2)
Neutropenia	30 (13.4)	12 (5.4)
Decreased appetite	41 (18.3)	0 (0.0)
Cough	26 (11.6)	0 (0.0)
Nasopharyngitis	26 (11.6)	0 (0.0)
Thrombocytopenia	18 (8.1)	6 (2.7)

Abbreviation: AE, adverse event.

^aPercentages are based on the number of subjects in the full analysis set.